아바델 파마슈티컬스(AVDL) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

🏛️

거래 정지 중인 종목 2026-06-04 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.

AVDL

Avadel Pharmaceuticals plc

$21.64

+0.00 +0.00%

아바델 파마슈티컬스(AVDL) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$2.1B

스몰캡

P/E

배당수익률

없음

52주 위치

89%

저점 +239% · 고점 -8%

애널리스트

보유

B+

Fundamental health

vs. 전체 시장

수익성

Top 28%

성장

Top 19%

밸류에이션

Top 11%

재무 안정

Top 41%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.01	Insider Own ⓘ	5.27%	Shs Outstand ⓘ	97.2M	Perf Week ⓘ	-
Market Cap ⓘ	2.12B	Forward P/E ⓘ	26.39	EPS next Y ⓘ	530.77%	Insider Trans ⓘ	-68.31%	Shs Float ⓘ	92.7M	Perf Month ⓘ	0.37%
Enterprise Value ⓘ	2.06B	PEG ⓘ	-	EPS next Q ⓘ	0.03	Inst Own ⓘ	75.91%	Short Float ⓘ	2.49%	Perf Quarter ⓘ	-5.58%
Income ⓘ	-0.00B	P/S ⓘ	8.52	EPS this Y ⓘ	125.49%	Inst Trans ⓘ	-1.91%	Short Ratio ⓘ	0.94	Perf Half Y ⓘ	45.72%
Sales ⓘ	0.25B	P/B ⓘ	21.42	EPS next 5Y ⓘ	-	ROA ⓘ	-0.16%	Short Interest ⓘ	2.31M	Perf YTD ⓘ	0.42%
Book/sh ⓘ	1.01	P/C ⓘ	23.11	EPS past 3/5Y ⓘ	27.03% 10.39%	ROE ⓘ	-0.32%	52W High ⓘ	-8.19% ($23.57)	Perf Year ⓘ	140.44%
Cash/sh ⓘ	0.94	P/FCF ⓘ	57.52	Sales past 3/5Y ⓘ	- 23.35%	ROIC ⓘ	-0.21%	52W Low ⓘ	239.18% ($6.38)	Perf 3Y ⓘ	178.87%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	251.54	EPS Y/Y TTM ⓘ	99.6%	Gross Margin ⓘ	94.47%	Volatility(W/M) ⓘ	0.48% 0.33%	Perf 5Y ⓘ	138.06%
Dividend TTM ⓘ	-	EV/Sales ⓘ	8.3	Sales Y/Y TTM ⓘ	79.88%	Oper. Margin ⓘ	1.82%	ATR (14) ⓘ	0.09	Perf 10Y ⓘ	134.96%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.37	EPS Q/Q ⓘ	100.73%	Profit Margin ⓘ	-0.11%	RSI (14) ⓘ	61.58	Recom ⓘ	3.17
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.76	Sales Q/Q ⓘ	54.86%	SMA20 ⓘ	0.38% ($21.56)	Beta ⓘ	1.31	Target Price ⓘ	$21
Payout ⓘ	-	Debt/Eq ⓘ	0.38	Earnings ⓘ	2025/11/4	SMA50 ⓘ	0.67% ($21.5)	Rel Volume ⓘ	0	Prev Close ⓘ	$21.64
Employees ⓘ	188	LT Debt/Eq ⓘ	0.37	EPS/Sales Surpr. ⓘ	-100% 5.29%	SMA200 ⓘ	40.29% ($15.43)	Avg Volume(3M) ⓘ	2.45M	Price ⓘ	$21.64
IPO ⓘ	1996/6/7	Option/Short ⓘ	Yes/No			Trades ⓘ	0	Volume ⓘ	-	Change ⓘ	-

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Avadel Pharmaceuticals plc (AVDL) Investment Analysis

What kind of company is Avadel Pharmaceuticals plc?

아바델 파마슈티컬스(AVDL)

Healthcare · Drug Manufacturers - Specialty & Generic

#1983 by Market Cap — Mid-Cap

💊 Specialty pharmaceutical company focused on sleep disorder treatment. LUMRYZ sales are growing rapidly. Q3 2025 revenue of $7.5M, with 3,400 patients. Alkermes acquisition in progress (Q1 2026).

Learn more about Avadel Pharmaceuticals plc →

Market Cap

$2.1B

Approx. KRW 2.9 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank1983

Employees188people

IPO1996/06/07

Current Price$21.64 ≈ 29,647원

NASD · Ireland

Key Events

예정된 이벤트가 없습니다

AVDL의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

실적 발표는 보통 분기마다 있습니다
배당주는 연 1~4회 배당락일이 있습니다

전체 경제/실적 캘린더 보기 →

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

1.8%

✓ 평균

My positionMid-range

Low range Average High range

전체 시장 Median 6.9% · Bottom 43%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-0.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

94.5%

✓ 우수

My positionTop 5%

Low range Average High range

전체 시장 Median 35.0% · Top tier

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-0.3%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-0.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-0.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.38

✓ Healthy debt

My positionMid-range

Low range Average High range

전체 시장 Median 0.40

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

2.76

✓ 양호

My positionMid-range

Low range Average High range

전체 시장 Median 1.70

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.37

✓ 양호

My positionMid-range

Low range Average High range

전체 시장 Median 1.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$21.00

현재가 대비 -3.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

26.39배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+530.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+125.5%

우수

My positionTop 5%

Low range Average High range

전체 시장 Median 15.0% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+530.8%

우수

My positionTop 5%

Low range Average High range

전체 시장 Median 15.7% · Top tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+27.0%

양호

My positionMid-range

Low range Average High range

전체 시장 Median 7.6% · Top 29%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+10.4%

양호

My positionMid-range

Low range Average High range

전체 시장 Median 9.7% · Top 49%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+23.4%

우수

My positionTop 25%

Low range Average High range

전체 시장 Median 9.6% · Top 21%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+54.9%

우수

My positionTop 25%

Low range Average High range

전체 시장 Median 6.5% · Top 12%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 70%p over 5 years

AVDL +138.1% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+69.7%p

well ahead of the market

vs Health Care (XLV)

+113.6%p

well ahead of the sector average

1-year basis

vs S&P 500

+124.4%p

well ahead of the market

vs Health Care (XLV)

+120.7%p

well ahead of the sector average

Current position within 52-week range

Low (-239.2%p) High (-8.2%p)

Current price is 239.2% above the 52-week low and 8.2% below the 52-week high

Recent risk (last 26 trading days)

Max drawdown

-0.3%

Annualized volatility

1.9%

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

26.39x

✓ Pricey

My positionBottom 25%

Low range Average High range

전체 시장 median 14.42x · Bottom 21% — expensive within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

21.42x

✓ Very pricey

My positionBottom 5%

Low range Average High range

전체 시장 median 1.76x · Bottom 1% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

8.52x

✓ Pricey

My positionBottom 25%

Low range Average High range

전체 시장 median 2.26x · Bottom 22% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

251.54x

✓ Very pricey

My positionBottom 5%

Low range Average High range

전체 시장 median 12.91x · Bottom 1% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

57.52x

✓ Pricey

My positionBottom 25%

Low range Average High range

전체 시장 median 16.21x · Bottom 12% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$21.00 vs. current price -3.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: 전체 시장

Who owns it?

Ownership flow shows some pressure

Insider net selling -68.3% · Institutional net selling -1.9% · Short interest light 2.5% · Short interest fell -0.5%p over the last 26 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-68.3%

Insiders large net selling

🏦 Institutions (funds & investors)

-1.9%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 75.9%

Adequate institutional weight

전체 시장 Median 48.6%

🧑‍💼 Insiders 5.3%

Meaningful insider stake

전체 시장 Median 12.2%

👤 Retail investors (estimated) 18.8%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

2.5%

Low — limited short-side pressure

전체 시장 Median 4.0%

Past 26 days 📉 -0.5%p decrease

Short interest days to cover

0.9 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 97.2M주

Float (tradable shares) 92.7M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 26 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
AVDL This Stock	$2.1B	-	21.4 ▼	-0.32% ▲	-	+0.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 아바델 파마슈티컬스(AVDL)?

아바델 파마슈티컬스(AVDL) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of AVDL?

The market cap of AVDL is approximately $2.1B, ranking 1,983 within its sector.

What is the 52-week high and low for AVDL?

AVDL has recorded a 52-week high of $23.57 and a low of $6.38.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.